Evidence map›Paper›PMID 41873388›Full record

ArticleNeuro-oncology advances

Integrated detection of cerebrospinal fluid cfDNA/cfRNA and molecular concordance with glioma characteristics.

Maoyuan Sun, Shan Jiang, Houshi Xu, Yulai Zeng, Beining Liu, Yue Wang, Zhen Li, Yun Guan, Jiawen Chen, Ruize Zhu and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Maoyuan SunDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Shan JiangDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-1015-126X
Houshi XuDepartment of Neurosurgery, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China.
Yulai ZengDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Beining LiuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Yue WangDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Zhen LiDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Yun GuanDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Jiawen ChenDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Ruize ZhuDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Weiqiu PingDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Yanlin TengDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Songlin YanDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Liying LiuKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd., Hangzhou, China.
Dan ShenKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd., Hangzhou, China.
Qisheng TangDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Zhen FanDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Ho-Keung NgDepartment of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong, China.
Zhiyong QinDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Ying MaoDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.
Zhifeng ShiDepartment of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China.ORCID https://orcid.org/0000-0003-1719-0456

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Accurate glioma diagnosis relies on tissue biopsy, which is often challenging. Liquid biopsy offers an alternative, but single-component circulating free DNA (cfDNA) or circulating free RNA (cfRNA) approaches have limited comprehensiveness. We developed and validated GlioKit, a platform for simultaneous cfDNA and cfRNA extraction from cerebrospinal fluid (CSF) to enhance diagnostic coverage, and evaluated its accuracy by correlating CSF-derived molecular profiles with tumor characteristics. Methods: We retrospectively analyzed 71 patients from the China Glioma Liquid Biopsy MultiOmics Atlas (C-Glioma) database, including 31 GBM, 36 IDH-mutant gliomas, and 4 diffuse midline gliomas (DMGs). Using GlioKit, we simultaneously extracted and analyzed CSF cfDNA and cfRNA, targeting 6 mutations ( Results: Among 71 glioma CSF samples, cfDNA mutations were detected in 55 (77%), cfRNA in 15 of 44 (34%). Overall, cfDNA-tumor concordance was 89%, and cfRNA was 73%. Subgroup analysis revealed cfDNA detection rates of 33/41 (surgery), 11/15 (Ommaya), and 11/15 (lumbar puncture); cfRNA detection rates were 5/25, 6/11, and 4/8, respectively. Corresponding concordance rates were cfDNA-30/33 (surgery), 10/11 (Ommaya), and 9/11 (lumbar puncture); cfRNA-4/5, 5/6, and 2/4. Conclusions: Cerebrospinal fluid-derived cfDNA and cfRNA variations closely align with tumor genomic alterations, validating CSF as a minimally invasive source for glioma molecular subtyping. GlioKit has potential for glioma diagnosis and therapy planning.

Indexed as

cerebrospinal fluidcfDNA/cfRNAgliomaliquid biopsy

Identifiers

PMID41873388
PMCPMC13006064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.